Table 1.
Baseline characteristics of patients treated with entecavir (ETV) or lamivudine (LAM).
| Total | ETV group | LAM group | P-values | |
|---|---|---|---|---|
| Number | 303 | 158 | 145 | |
| Age (years) | 51 ± 12 | 51 ± 12 | 50 ± 12 | N.S. |
| Gender (male) | 205 | 101 | 104 | N.S. |
| HBeAg (+) | 146 | 84 | 62 | 0.079 |
| HBV DNA (log IU/mL) | 6.5 ± 1.5 | 6.6 ± 1.7 | 6.4 ± 1.3 | N.S. |
| ALT (IU/L) | 203 ± 280 | 187 ± 290 | 220 ± 266 | N.S. |
| US: Cirrhosis (+) | 113 | 56 | 57 | N.S. |
| Periods to undetectable HBV DNA (months) | 10.0 ± 18.2 | 8.5 ± 11.9 | 11.8 ± 23.3 | N.S. |
Data are expressed as mean ± SD. ETV group, patients receiving 0.5 mg of ETV daily; LAM group, patients receiving 100 mg of LAM daily; P-values, P-values between ETV and LAM groups; HBeAg, hepatitis B e antigen; ALT, alanine aminotransferase; US, ultrasound findings; N.S., no statistically significant difference.